{"success":true,"data":{"pressRelease":{"id":"166218","rtpr_id":"nGNX4Md1wh-20261012","ticker":"VANI","exchange":"NASDAQ","all_tickers":["VANI"],"title":"Vivani Medical Announces Participation in Upcoming Investor Conferences","author":"Globe Newswire","published_at":"2026-10-12T11:00:00.340Z","article_body":"ALAMEDA, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc.\n(Nasdaq: VANI) (\"Vivani\" or the \"Company\"), a clinical-stage biopharmaceutical\ncompany developing miniature, ultra-long-acting drug implants utilizing its\nproprietary NanoPortal™ technology, today announced its participation in two\ninvestor conferences taking place this week in New York, New York:\n\nMaxim Growth Summit\nOctober 14, 2026\nHard Rock Hotel New York\n\nThe ThinkEquity Conference\nOctober 15, 2026\nMandarin Oriental\n\nMembers of the Vivani management team will host investor and partner meetings\nat both conferences. Vivani’s participation in The ThinkEquity Conference on\nOctober 15 will include a presentation from Chief Executive Officer Adam\nMendelsohn, Ph.D. Any webcasts will be available following the conferences on\nthe Investors page of the Vivani corporate website.\n\nAbout Vivani Medical, Inc.\n\nLeveraging its proprietary NanoPortal™ platform, Vivani develops miniature,\nbiopharmaceutical implants designed to deliver drug molecules steadily over\nextended periods of time with the goal of guaranteeing adherence and improving\npatient tolerance to their medication. Vivani is developing a portfolio of\nGLP-1 based implants for metabolic diseases including obesity and type 2\ndiabetes. These NanoPortal implants are designed for once- or twice-yearly\nadministration to provide patients with the opportunity to realize the full\npotential benefit of their medication by avoiding the numerous challenges\nassociated with the daily or weekly administration of orals and injectables,\nincluding tolerability issues and loss of efficacy. Medication non-adherence\noccurs when patients do not take their medication as prescribed. This affects\nan alarming number of patients, approximately 50%, including those taking\ndaily pills. For more information, please visit: www.vivani.com.\n\nForward-Looking Statements\n\nThis press release contains certain “forward-looking statements” within\nthe meaning of the “safe harbor” provisions of the U.S. Private Securities\nLitigation Reform Act of 1995. Forward-looking statements can be identified by\nwords such as: “target,” “believe,” “expect,” “will,”\n“may,” “anticipate,” “estimate,” “would,” “positioned,”\n“future,” and other similar expressions that are used in this press\nrelease, including statements regarding Vivani’s business, products in\ndevelopment, including the therapeutic potential or the planned development\nthereof, and its technology, strategy, cash position and financial runway.\nForward-looking statements are neither historical facts nor assurances of\nfuture performance. Instead, they are based only on Vivani’s current\nbeliefs, expectations, and assumptions. Because forward-looking statements\nrelate to the future, they are subject to inherent uncertainties, risks and\nchanges in circumstances that are difficult to predict and many of which are\noutside of Vivani’s control. These statements involve risks and\nuncertainties that could cause actual results to differ materially from those\nreflected in such statements, including, without limitation, risks of\nunexpected costs or delays, and risks and uncertainties associated with the\ndevelopment and commercialization of products and product candidates that may\nimpact or alter anticipated business plans, strategies and objectives. Actual\nresults and outcomes may differ materially from those indicated in the\nforward-looking statements. Therefore, you should not rely on any of these\nforward-looking statements. The foregoing sets forth many, but not all, of the\nfactors that could cause actual results to differ from Vivani’s expectations\nin any forward-looking statement. There may be additional risks that the\nCompany considers immaterial, or which are unknown. A further list and\ndescription of risks and uncertainties are more fully described in periodic\nfilings with the U.S. Securities and Exchange Commission (the “SEC”)\nincluding the factors described in Vivani’s most recent Quarterly Report on\nForm 10-Q filed with the SEC on August 13, 2026, as updated by future filings\nwith the SEC. Any forward-looking statement made by Vivani in this press\nrelease is based only on information currently available to the Company and\nspeaks only as of the date of this press release. The Company undertakes no\nobligation to publicly update any forward-looking statement, whether written\nor oral, that may be made from time to time, whether as a result of added\ninformation, future developments or otherwise, except as required by law.\n\nCompany Contact:\nDonald Dwyer\nChief Business Officer\ninfo@vivani.com\n(415) 506-8462\n\nInvestor and Media Relations Contact:\nJami Taylor\nInvestor and Media Relations Advisor\ninvestors@vivani.com\n(415) 506-8462\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/d1946b5d-9232-4b97-9682-fa050b6fb31f)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX4Md1wh-20261012","title":"Vivani Medical Announces Participation in Upcoming Investor Conferences","author":"Globe Newswire","ticker":"VANI","created":"2026-10-12T11:00:00.340Z","tickers":["VANI"],"exchange":"NASDAQ","article_body":"ALAMEDA, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc.\n(Nasdaq: VANI) (\"Vivani\" or the \"Company\"), a clinical-stage biopharmaceutical\ncompany developing miniature, ultra-long-acting drug implants utilizing its\nproprietary NanoPortal™ technology, today announced its participation in two\ninvestor conferences taking place this week in New York, New York:\n\nMaxim Growth Summit\nOctober 14, 2026\nHard Rock Hotel New York\n\nThe ThinkEquity Conference\nOctober 15, 2026\nMandarin Oriental\n\nMembers of the Vivani management team will host investor and partner meetings\nat both conferences. Vivani’s participation in The ThinkEquity Conference on\nOctober 15 will include a presentation from Chief Executive Officer Adam\nMendelsohn, Ph.D. Any webcasts will be available following the conferences on\nthe Investors page of the Vivani corporate website.\n\nAbout Vivani Medical, Inc.\n\nLeveraging its proprietary NanoPortal™ platform, Vivani develops miniature,\nbiopharmaceutical implants designed to deliver drug molecules steadily over\nextended periods of time with the goal of guaranteeing adherence and improving\npatient tolerance to their medication. Vivani is developing a portfolio of\nGLP-1 based implants for metabolic diseases including obesity and type 2\ndiabetes. These NanoPortal implants are designed for once- or twice-yearly\nadministration to provide patients with the opportunity to realize the full\npotential benefit of their medication by avoiding the numerous challenges\nassociated with the daily or weekly administration of orals and injectables,\nincluding tolerability issues and loss of efficacy. Medication non-adherence\noccurs when patients do not take their medication as prescribed. This affects\nan alarming number of patients, approximately 50%, including those taking\ndaily pills. For more information, please visit: www.vivani.com.\n\nForward-Looking Statements\n\nThis press release contains certain “forward-looking statements” within\nthe meaning of the “safe harbor” provisions of the U.S. Private Securities\nLitigation Reform Act of 1995. Forward-looking statements can be identified by\nwords such as: “target,” “believe,” “expect,” “will,”\n“may,” “anticipate,” “estimate,” “would,” “positioned,”\n“future,” and other similar expressions that are used in this press\nrelease, including statements regarding Vivani’s business, products in\ndevelopment, including the therapeutic potential or the planned development\nthereof, and its technology, strategy, cash position and financial runway.\nForward-looking statements are neither historical facts nor assurances of\nfuture performance. Instead, they are based only on Vivani’s current\nbeliefs, expectations, and assumptions. Because forward-looking statements\nrelate to the future, they are subject to inherent uncertainties, risks and\nchanges in circumstances that are difficult to predict and many of which are\noutside of Vivani’s control. These statements involve risks and\nuncertainties that could cause actual results to differ materially from those\nreflected in such statements, including, without limitation, risks of\nunexpected costs or delays, and risks and uncertainties associated with the\ndevelopment and commercialization of products and product candidates that may\nimpact or alter anticipated business plans, strategies and objectives. Actual\nresults and outcomes may differ materially from those indicated in the\nforward-looking statements. Therefore, you should not rely on any of these\nforward-looking statements. The foregoing sets forth many, but not all, of the\nfactors that could cause actual results to differ from Vivani’s expectations\nin any forward-looking statement. There may be additional risks that the\nCompany considers immaterial, or which are unknown. A further list and\ndescription of risks and uncertainties are more fully described in periodic\nfilings with the U.S. Securities and Exchange Commission (the “SEC”)\nincluding the factors described in Vivani’s most recent Quarterly Report on\nForm 10-Q filed with the SEC on August 13, 2026, as updated by future filings\nwith the SEC. Any forward-looking statement made by Vivani in this press\nrelease is based only on information currently available to the Company and\nspeaks only as of the date of this press release. The Company undertakes no\nobligation to publicly update any forward-looking statement, whether written\nor oral, that may be made from time to time, whether as a result of added\ninformation, future developments or otherwise, except as required by law.\n\nCompany Contact:\nDonald Dwyer\nChief Business Officer\ninfo@vivani.com\n(415) 506-8462\n\nInvestor and Media Relations Contact:\nJami Taylor\nInvestor and Media Relations Advisor\ninvestors@vivani.com\n(415) 506-8462\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/d1946b5d-9232-4b97-9682-fa050b6fb31f)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-12T11:00:00.397411259Z","server_sent_at_ms":1791802800397},"received_at":"2026-10-12T11:00:00.494Z","source_url":null},"analysis":{"id":"154579","press_release_id":"166218","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Vivani Medical announced it will participate in two investor conferences in New York this week: the Maxim Growth Summit on October 14 and The ThinkEquity Conference on October 15.\n\nCEO Adam Mendelsohn will present at The ThinkEquity Conference, and management will host investor and partner meetings at both events.\n\nNo new clinical, financial, or regulatory details were disclosed; this is routine investor-outreach news.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine investor conference schedule notice -- no material new information."},"keyFigures":{},"namedEntities":{"people":[{"name":"Adam Mendelsohn, Ph.D.","role":"Chief Executive Officer"},{"name":"Donald Dwyer","role":"Chief Business Officer"},{"name":"Jami Taylor","role":"Investor and Media Relations Advisor"}],"products":["NanoPortal™"],"companies":[{"name":"Vivani Medical, Inc.","ticker":"VANI"},{"name":"Maxim Growth Summit","relationship":"conference host"},{"name":"The ThinkEquity Conference","relationship":"conference host"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine announcement of investor conference participation and a management presentation; no new financial, clinical, or regulatory information disclosed."},"tickerRelevance":{"others":[],"primary":"VANI"},"globalImportance":5,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"conference-participation-notice","issuerAuthored":true}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Vivani Medical announced it will participate in two investor conferences in New York this week: the Maxim Growth Summit on October 14 and The ThinkEquity Conference on October 15.\n\nCEO Adam Mendelsohn will present at The ThinkEquity Conference, and management will host investor and partner meetings at both events.\n\nNo new clinical, financial, or regulatory details were disclosed; this is routine investor-outreach news.","key_figures":{},"named_entities":{"people":[{"name":"Adam Mendelsohn, Ph.D.","role":"Chief Executive Officer"},{"name":"Donald Dwyer","role":"Chief Business Officer"},{"name":"Jami Taylor","role":"Investor and Media Relations Advisor"}],"products":["NanoPortal™"],"companies":[{"name":"Vivani Medical, Inc.","ticker":"VANI"},{"name":"Maxim Growth Summit","relationship":"conference host"},{"name":"The ThinkEquity Conference","relationship":"conference host"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-12T11:00:04.360Z","global_importance":5,"audience_relevance":10,"importance_components":{"tickerTier":"micro-cap","eventGravity":"conference-participation-notice","issuerAuthored":true}},"durationMs":3853,"modelName":"glm-5.3-flashx"}}